| Document |
Document Title |
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/059508A3 |
The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a joint that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conv...
|
|
WO/2024/094170A1 |
Disclosed are an inhibitor compound of ubiquitin-specific protease 1 and a use thereof. The inhibitor compound specifically relates to a compound represented by formula (I) or an enantiomer, a diastereomer, a racemate, a tautomer, a ster...
|
|
WO/2024/097901A1 |
. Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional...
|
|
WO/2024/097904A1 |
This disclosure provides, among other things, an engineered immunosuppressive (e.g., CD4+) T cell comprising a molecular circuit comprising the following components: (a) a central nervous system (CNS)-specific binding-triggered transcrip...
|
|
WO/2024/097206A1 |
The present invention relates to Compound (A), pharmaceutically acceptable salts thereof, methods of making, and use thereof optionally in combination with one or more additional therapeutic agents for the treatment of disease.
|
|
WO/2024/095175A1 |
Anti SLC2A1 antibodies and antigen binding fragments thereof are disclosed. The antibodies and the fragments are suitable for use in inhibiting tumor cell glucose uptake and for reprogramming tumor cell metabolism toward oxidative phosph...
|
|
WO/2024/096735A1 |
The invention provides single domain heavy chain variable antibodies that specifically bind CD169. The invention further relates to methods of modulating an immune response in an individual using the single heavy chain variable domain an...
|
|
WO/2024/096708A1 |
The present disclosure relates to solid forms of pyrimidine compounds, pharmaceutical compositions including the same and methods of use thereof. For example, the disclosure relates to crystalline polymorphs of a compound of Formula 1, o...
|
|
WO/2024/036207A3 |
The invention provides antibodies, antibody fragments or antigen-binding fragments, as well as related antibody drug conjugates (ADCs) and chimeric antigen receptors (CARs), that specifically recognize a multiple myeloma cell surface ant...
|
|
WO/2024/098075A1 |
The present disclosure, at least in part, relates to compositions comprising invariant natural kill T (iNKT) cells (e.g., unmodified, allogeneic iNKT cells), and methods of using the compositions comprising the iNKT cells for treating a ...
|
|
WO/2024/098032A1 |
Compositions and methods for treating ependymoma, including RELA fusion‑positive ependymoma refractory to temozolomide-based regimens. Methods comprise administering a therapeutically effective amount of an alkylating hexitol or deriva...
|
|
WO/2024/097948A1 |
Provided herein are compounds, including compounds of Formula (I) (e.g., compounds of Formula (I-a)), and pharmaceutically acceptable salts, stereoisomers, tautomers, isotopically labeled derivatives, solvates, hydrates, polymorphs, co-c...
|
|
WO/2024/096624A1 |
The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-1-yl)piperidin-1-yl)-5-(
(6-(3-(3,5-difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)a
mino)-4-methoxyp...
|
|
WO/2024/092740A1 |
Provided is a method for detecting intercellular interaction. The method comprises: (1) preparing a first cell expressing a TCR activation response element and a reporter molecule, the first cell expressing a TCR; (2) co-incubating an an...
|
|
WO/2024/098001A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as mel...
|
|
WO/2024/094526A1 |
The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer.
|
|
WO/2024/095006A1 |
The present invention relates to a therapeutic agent comprising an autoregulation element, preferably wherein the therapeutic agent is an antigen binding protein. Methods of treatment comprising use of said agent are also disclosed.
|
|
WO/2024/094171A1 |
A substituted aminopyrimidine compound, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, in particular as an EGFR inhibitor and/or degradation agent and the us...
|
|
WO/2024/097800A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Also provided are derivative cells having stable and functional g...
|
|
WO/2024/097953A1 |
The present disclosure relates to compounds (I) and compositions for inhibition of RAF serine/threonine protein kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers.
|
|
WO/2024/097940A1 |
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A. Provided herein are also methods of treating and/or managing cancers, which comprise administering to a patient Compou...
|
|
WO/2024/072931A3 |
The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a the...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/050056A3 |
Provided are modified arginine deiminase (ADI) proteins, including ADI proteins that comprise one or more substitutions which increase expression in bacteria as insoluble and refoldable inclusion bodies. Also provided are methods of prod...
|
|
WO/2024/062072A3 |
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof, which specifically binds to human CCR8 and is an antagonist of the CCL1-CCR8 signaling pathway, particularly wherein the antibody or antigen-b...
|
|
WO/2024/093652A1 |
The present invention discloses a nanobody targeting IL-6Rα protein and uses thereof, wherein the heavy chain variable region of the nanobody comprises three complementary determining regions, CDR1, CDR2, and CDR3, wherein CDR1 has an a...
|
|
WO/2024/095964A1 |
The present invention addresses the problem of developing an antibody-drug complex containing a TLR7/8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types ...
|
|
WO/2024/097945A1 |
The present technology is directed to a compound of Formula I: or a pharmaceutically acceptable salt and/or solvate thereof, and pharmaceutical compositions or medicaments comprising the compound. The compounds, pharmaceutical compositio...
|
|
WO/2024/097848A1 |
The present application provides salts and crystalline forms, and polymorphic crystalline forms of (R)-N-(2-(4-(4-cyclopropylpiperazin-l-yl)piperidin-l-yl)-5-(
(6-(3-(3,5- difluorophenyl)isoxazolidin-2-yl)pyrimidin-4-yl)amino)-4-met
hoxy...
|
|
WO/2024/094211A1 |
The present invention relates to mucosal drug delivery systems, and specifically to a lipid composition; the lipid composition containing a therapeutic agent and/or prophylactic agent such as RNA can be used for mucosal delivery of the t...
|
|
WO/2024/097814A1 |
The invention provides methods for upregulating mitochondrial and/or glycolytic metabolism in T cells by increasing the flux of pyruvate into the citric acid cycle, thereby increasing mitochondrial and/or glycolytic metabolism. In genera...
|
|
WO/2023/107842A3 |
This disclosure is based, at least in part, on unexpected discoveries that a novel composition of a leukotoxin (LtxA) polypeptide isolated from Aggregatibatier actin omycetcmcomitans can retain stability and biological activities for an ...
|
|
WO/2024/097877A1 |
Provided herein are ZP4 antibodies and ZP4-specific chimeric antigen receptors (CARs). Further provided herein are immune cells expressing the ZP4-specific CARs and methods of treating cancer by administering the ZP4-specific CAR immune ...
|
|
WO/2024/097251A1 |
In one aspect, the present disclosure describes methods which may be used to create ICWs and thereby regulate calcium signaling. These methods may employ a light-stimulated MM to generate an ICW and that ICW may be used to induce muscle ...
|
|
WO/2024/094163A1 |
Disclosed are a polycyclic ring-fused derivative, a preparation method therefor, and use thereof. In particular, disclosed are a compound represented by general formula (I-2-1), a preparation method therefor, a pharmaceutical composition...
|
|
WO/2024/097950A1 |
Disclosed herein is an antibody-conjugate comprising a monoclonal antibody that specifically binds to GD2 and comprises a heavy chain and a light chain comprising heavy and light chain variable regions set forth as SEQ ID NOs: 3 and 4, r...
|
|
WO/2024/097977A1 |
Methods disclosed herein relate to generating silk nanoparticles with a low polydispersity index (PDI). Methods include adding a silk solution dropwise into a volatile solvent that is miscible with water, thereby forming a precipitate-be...
|
|
WO/2024/094688A1 |
In a first aspect the present application pertains to an anti-GUCY2C antibody, corresponding antibody-drug conjugates comprising amatoxin for use in the treatment of gastrointestinal cancers, such as colorectal cancer, and pancreatic can...
|
|
WO/2024/097270A1 |
The present disclosure provides improved methods of treating non-small cell lung cancer characterized by EGFR mutation using Compound (I): or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/097418A2 |
Provided herein are gene activation and interference targets for exhaustion/dysfunction-resistant t cell products and uses thereof.
|
|
WO/2024/094159A1 |
Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
|
|
WO/2024/097989A1 |
The present disclosure relates to protein degradation inducing compounds for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorde...
|
|
WO/2024/097200A1 |
Provided are methods for treating colorectal cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).
|
|
WO/2024/097653A1 |
Methods for treatment of myeloproliferative neoplasms are provided, particularly in patients with poor bone marrow functioning, and difficult to treat human patients such as those with relapsed or refractory disease. The disclosed method...
|
|
WO/2024/097721A1 |
The disclosure relates to the use of inhibitors of phosphoinositide 3-kinase (PI3K) that target allosteric and orthosteric pockets of PI3K in methods of treating, preventing, or ameliorating a disease, or disorder, (or uses in the treatm...
|
|
WO/2024/097767A1 |
The present disclosure provides methods for treating a cancer such as an advanced solid tumor in a subject in need thereof by administering to the subject in need thereof an effective first dose of an IL- 12 albumin binding domain (ABD) ...
|
|
WO/2024/098019A1 |
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...
|
|
WO/2024/097642A1 |
The present disclosure relates to methods of increasing the efficacy of adoptive cell therapy (ACT) and methods of treating cancer, wherein the methods include administering to a subject with cancer in need thereof a combination therapy ...
|
|
WO/2024/097856A1 |
The present disclosure is based on the identification of copy number of DPP9 gene and expression of a set of genes as biomarkers predictive of responsiveness to DPP inhibitors, particularly Talabostat or a pharmaceutically acceptable sal...
|
